EVEREST-HN 1: EVolution of a patiEnt-REported Symptom-based Risk Stratification sySTem

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

165 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-03-17

Study Completion Date

2023-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Can a patient-reported symptom-based risk stratification system improve the suspected head and neck cancer (HNC) pathway?

Our methodology includes six interlinked work packages to deliver our aim, with EVEREST-HN 1 encompassing the first of these and seeking to optimise a patient-reported symptom inventory for HNC and outline requirement specification for the SYmptom iNput Clinical (SYNC) system.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Customized Registry Tool for Tracking Adherence to Clinical Guidelines for Head and Neck Cancers

NCT03546322

Head and Neck Neoplasms

COMPLETED

Intensive Symptom Surveillance Guided by Machine Learning-Directed Risk Stratification in Patients With Non-Metastatic Head and Neck Cancer, The INSIGHT Trial

NCT05338905

Head and Neck Squamous Cell Carcinoma

ACTIVE_NOT_RECRUITING NA

Quick Diagnostic Program for Head and Neck Cancer

NCT02030509

Cancer of Head and Neck

COMPLETED

SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)

NCT02543476

Squamous Cell Carcinoma of the Head and Neck

COMPLETED

Head and Neck cancERs International cOviD-19 collabOraTion

NCT04632173

Head and Neck Cancer Covid19

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The EVEREST-HN pathway should be based on a comprehensive understanding of existing HNC diagnostic pathways and what patients and clinicians value in these. The language used within the EVEREST pathway needs to be accessible and optimal to elicit appropriate information.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Head and Neck Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients

Approximately 150 adults referred for suspected HNC will be recruited.

No intervention.

Intervention Type OTHER

No intervention.

Staff

Approximately 15 ENT and Maxillofacial) clinicians will be recruited.

No intervention.

Intervention Type OTHER

No intervention.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients:

* Adults ≥ 18 years referred via suspected HNC pathway without previous history of HNC
* Participants willing and able to give informed consent for participation in the study.

Clinicians:

* Staff at participating sites involved in the diagnostic pathway for people with suspected HNC.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No